This comprehensive guide offers medically accurate and patient-friendly information on Myelodysplastic Syndrome (MDS), presented in a clear, empathetic, and professional tone.
Myelodysplastic Syndrome (MDS) is the collective term for a group of blood cancers where the bone marrow—the soft, spongy tissue inside your bones responsible for producing blood cells—fails to generate enough healthy, mature blood cells. Instead, the bone marrow produces an excessive number of immature cells, often referred to as blasts.
These unhealthy blasts frequently die prematurely within the bone marrow or shortly after entering the bloodstream. This process results in a deficiency of healthy, mature blood cells and consequently, abnormally low blood counts, a condition known as cytopenia.
In its less severe forms, MDS may initially manifest as anaemia (a low red blood cell count), a low platelet count, or a low white blood cell count. Importantly, it is estimated that approximately 10% to 20% of diagnosed MDS cases can progress to a more aggressive blood cancer called Acute Myeloid Leukaemia (AML).
To gain a clearer understanding of MDS, it is helpful to know the basic components of normal, healthy blood:
These cells are vital for transporting oxygen from your lungs to every part of your body and carrying carbon dioxide back. A low RBC count causes anaemia, leading to common symptoms like fatigue, generalised weakness, and shortness of breath. The oxygen-carrying protein in RBCs is called haemoglobin.
These are the body's primary line of defence, protecting against infection and germs. The major types include:
When WBCs are low, the risk of developing an infection increases. The Absolute Neutrophil Count (ANC) is a critical measurement of your body's ability to fight infection; it is calculated by multiplying the total WBC count by the percentage of neutrophils.
These small cells are essential for controlling bleeding. When an injury occurs, platelets rapidly gather at the site to form a plug, which stops the blood loss.
This is the origin of all blood cells. They begin as highly immature cells called stem cells. When the body requires new blood cells, "growth factors" signal these stem cells to mature into healthy RBCs, WBCs, or platelets. Once fully mature, they are released into the bloodstream, or peripheral blood.
MDS is categorised into various types based on the quantity of abnormal cells (blasts) found in the blood and bone marrow. These types include:
Refractory anaemia
Refractory cytopenia with multilineage dysplasia
Refractory anaemia with ringed sideroblasts
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
Refractory anaemia with excess blasts
While the precise cause of most MDS cases is not known, several factors have been identified as potentially increasing the risk:
MDS is considered rare in individuals younger than 60 years of age.
Use of tobacco products.
Prolonged exposure to certain chemicals, such as benzene or substances used in the petroleum and rubber industries.
Exposure to high levels of radiation, for example, from a nuclear reactor accident or atomic bomb.
Previous treatment with chemotherapy or radiation therapy for an unrelated condition.
This includes conditions such as Fanconi anaemia, Shwachman-Diamond syndromes, Familial platelet disorder, and Severe congenital neutropenia.
In its earliest stages, MDS often presents with no discernible symptoms. When signs do manifest, they can be non-specific and easily mistaken for other health problems. Symptoms can vary significantly from one individual to the next but may include:
If you experience any persistent symptoms, it is crucial to discuss them with your doctor, as they may indicate MDS or another underlying health concern.
The accurate diagnosis of myelodysplastic syndrome is often complex and demands specialist expertise. At SSCHRC, our medical experts are highly skilled in diagnosing this rare condition using the most advanced techniques and technology available.
If MDS is suspected based on your symptoms and medical history, your doctor will conduct a physical examination and enquire about your overall health, lifestyle (including smoking habits), and family medical history.
Performed to check blood cell counts and look for the presence of abnormal cells.
Bone marrow biopsy: A small solid sample of bone and marrow is carefully removed.
Bone marrow aspiration: A small amount of liquid bone marrow is drawn out.
SSCHRC offers access to the most advanced treatments, including numerous clinical trials of innovative therapies developed through groundbreaking research. Treatment is typically stratified based on the patient's risk level:
Initial treatment generally focuses on managing specific complications, such as anaemia and other low blood counts.
If more intensive therapy becomes necessary, standard-of-care options often involve the use of hypomethylating agents (such as 5-azacitidine and decitabine) and lenalidomide.
These cases usually require a more aggressive therapeutic approach, which is personalised according to the patient's age and general health status.
Younger patients with high-risk disease may be candidates for front-line chemotherapy regimens, potentially followed by an allogeneic stem cell transplantation.
For older patients, intensive chemotherapy is less frequently utilised. Instead, the focus is placed on developing safe and active treatments for those who are newly diagnosed, as well as for patients who have not responded effectively to standard-of-care therapies.